RxDoctor Payments Data

Janet Goodfellow, MD

Family Medicine · Irvine, CANPI 1407888035

Payments from drug & device makers

$2,300in general payments, 2019–2025

Across 100 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$767
  • Amgen$289
  • Astellas Pharma US Inc$261
  • Sanofi-aventis U.S. LLC$150
  • Merck$144
  • Amarin Pharma, Inc.$113
  • plus $575 from 14 others

What the payments were for

  • Consulting fees$1758%
  • Speaking & faculty fees$1507%
  • Food & beverage$1,90083%
  • Education$753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,300 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$34,363
Medicare patients
111
Services billed
334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$54,402
ProliaDenosumab26$44,548
FarxigaDapagliflozin Propanediol18$28,050
MyrbetriqMirabegron14$17,409
Wixela InhubFluticasone Propion/Salmeterol16$4,352
Levothyroxine Sodium280$4,257
Valsartan134$3,607
Atorvastatin Calcium344$3,522
Rosuvastatin Calcium167$3,506
Estradiol24$3,297
SynthroidLevothyroxine Sodium54$2,279
Metformin Hcl ErMetformin Hcl140$1,737
Metoprolol Succinate89$1,707
Duloxetine Hcl56$1,696
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide49$1,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$98$54,40241 claims
AmgenProlia$289$44,54826 claims
AstraZenecaFarxiga$767$28,05018 claims
Astellas Pharma US IncMyrbetriq$261$17,40914 claims
AbbVieSynthroid$35$2,27954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →